Medpace Holdings, Inc. · NASDAQ:MEDP
Medpace — Q3 2026 Earnings Presentation
15 slides from Medpace's earnings presentation, Oct 21, 2026
Slide 1: Q3 2026 Financial Results
Q3 2026 FINANCIAL RESULTS OCTOBER 21, 2026
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of histori
Slide 3: Q3 2026 – Key Operating Highlights
Q3 2026 – KEY OPERATING HIGHLIGHTS ($ in millions) Third Quarter Year-to-Date 2026 2025 % Change 2026 2025 % Change Revenue, net $ 716.0 $ 659.9 8.5 % $ 2,129.9 $ 1,821.8 16.9 % Net New Business Awards $ 873.4 $ 789.6 10.6 % $ 2,287.6 $ 1,910.2 19.8 % Net New Business Awards (LTM) (A) $ 3,024.2 $ 2,
Slide 4: Backlog and New Award Trends
BACKLOG AND NEW AWARD TRENDS Net New Business Awards Backlog Conversion Rate LTM Net New Business Awards Ending Backlog and Est. NTM Backlog Conversion(A) (A) Represents estimated midpoint of NTM conversion(A) ($ in millions) A. Amount of backlog estimated to convert to revenue in the next twelve mo
Slide 5: Q3 2026 – Key Financial Highlights
Q3 2026 – KEY FINANCIAL HIGHLIGHTS ($ in millions, except per share data) Third Quarter Year-to-Date 2026 2025 % Change(B) 2026 2025 % Change(B) Revenue, net $ 716.0 $ 659.9 8.5 % $ 2,129.9 $ 1,821.8 16.9 % EBITDA(A) $ 172.1 $ 148.4 16.0 % $ 474.9 $ 397.5 19.5 % % Margin 24.0 % 22.5 % n.m. 22.3 % 21
Slide 6: Key Financial Trends
KEY FINANCIAL TRENDS ($ in millions) ($ in millions) Revenue, net EBITDA(A) Represents percent of Revenue ($ in millions) Net Income Net Income per diluted share A. See the appendix for the non-GAAP reconciliation of the EBITDA calculations. 6 MAKING THE COMPLEX SEAMLESS
Slide 7: Key Financial Trends
KEY FINANCIAL TRENDS ($ in millions) Revenue +12.0% - 12.8% YOY +20.0% YOY +11.8% YOY +29.2% YOY +27.8% YOY Guidance Range $2,835 - $2,855 ($ in millions) EBITDA(A) +14.4% - 16.9% YOY +16.1% YOY +32.5% YOY +17.7% YOY Guidance Range +38.1% YOY $638 - $652 A. See the appendix for the non-GAAP reconcil
Slide 8: Key Financial Trends
KEY FINANCIAL TRENDS ($ in millions) Net Income +13.9% - 16.2% YOY +11.6% YOY +43.0% YOY +15.3% YOY +34.9% YOY Guidance Range $514 - $524 Net Income per diluted share +17.6% - 19.9% YOY +21.0% YOY +42.2% YOY +22.0% YOY +51.4% YOY Guidance Range $17.97 - $18.32 8 MAKING THE COMPLEX SEAMLESS
Slide 9: Revenue Composition
REVENUE COMPOSITION Therapeutic Area Customer Tier Top 10 Customer Concentration Concentration(B) Concentration (A) Large Mid-sized Pharma Biopharma Top 5 Q3 2026 LTM Small All Other Biopharma Rest of Top 10 (A) Mid-sized Large Top 5 Biopharma Pharma Q3 2025 LTM Rest of Small Top 10 All Other Biopha
Slide 10: Q3 2026 – Cash Position
Q3 2026 – CASH POSITION ($ in millions) ($ in millions) Third Quarter Year-to-Date Free Cash Flow and Free Cash Flow Conversion(A) Free Cash Flow 2026 2025 2026 2025 (A) Operating Cash Flow $ 216.6 $ 246.2 $ 530.4 $ 520.6 (GAAP) Less: CAPEX 20.2 10.7 50.9 26.8 Free Cash Flow $ 196.4 $ 235.5 $ 479.5
Slide 11: Full Year 2026 Guidance
FULL YEAR 2026 GUIDANCE ($ in millions, except per share data) As of July 22, 2026 As of October 21, 2026 Guidance Range Growth Rate Guidance Range Growth Rate Revenue, net $2,805.0 - $2,885.0 10.9% - 14.0% $2,835.0 - $2,855.0 12.0% - 12.8% EBITDA $618.0 - $642.0 10.8% - 15.1% $638.0 - $652.0 14.4%
Slide 12: Appendix
APPENDIX Histt
Slide 13: Q3 2026 – Income Statement
Q3 2026 – INCOME STATEMENT % % Revenue, Revenue, 3Q26 vs. 3Q25 ($ in millions, except per share amounts) 3Q26 net 3Q25 net $ Change % Change Revenue, net $ 716.0 100.0 % $ 659.9 100.0 % $ 56.1 8.5 % Operating expenses: Direct service costs, excluding depreciation and amortization 204.9 28.6 % 186.3
Slide 14: EBITDA Reconciliation
EBITDA RECONCILIATION YTD YTD ($ in millions) 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 2025 2026 Net income as reported (GAAP) $117.0 $114.6 $ 90.3 $111.1 $135.1 $123.9 $121.4 $137.5 $ 316.0 $ 382.7 Income tax provision 16.9 3.6 34.3 31.7 21.7 23.7 30.3 33.4 69.6 87.5 Interest income, net (7.9) (6.5)
Slide 15: FY2026 Guidance Reconciliation
FY2026 GUIDANCE RECONCILIATION ($ in millions, except per share amounts) Net Income per diluted Net Income share Low High Low High Net income and net income per diluted share (GAAP) $ 514.0 $ 524.0 $ 17.97 $ 18.32 Income tax provision 119.5 123.5 Interest income, net (22.9) (22.9) Depreciation 26.8